Literature DB >> 23562672

Optimising monitoring in the management of Crohn's disease: a physician's perspective.

Pavol Papay1, Ana Ignjatovic, Konstantinos Karmiris, Heda Amarante, Pal Milheller, Brian Feagan, Geert D'Haens, Philippe Marteau, Walter Reinisch, Andreas Sturm, Flavio Steinwurz, Laurence Egan, Julián Panés, Edouard Louis, Jean-Frédéric Colombel, Remo Panaccione.   

Abstract

Management of Crohn's disease has traditionally placed high value on subjective symptom assessment; however, it is increasingly appreciated that patient symptoms and objective parameters of inflammation can be disconnected. Therefore, strategies that objectively monitor inflammatory activity should be utilised throughout the disease course to optimise patient management. Initially, a thorough assessment of the severity, location and extent of disease is needed to ensure a correct diagnosis, identify any complications, help assess prognosis and select appropriate therapy. During follow-up, clinical decision-making should be driven by disease activity monitoring, with the aim of optimising treatment for tight disease control. However, few data exist to guide the choice of monitoring tools and the frequency of their use. Furthermore, adaption of monitoring strategies for symptomatic, asymptomatic and post-operative patients has not been well defined. The Annual excHangE on the ADvances in Inflammatory Bowel Disease (IBD Ahead) 2011 educational programme, which included approximately 600 gastroenterologists from 36 countries, has developed practice recommendations for the optimal monitoring of Crohn's disease based on evidence and/or expert opinion. These recommendations address the need to incorporate different modalities of disease assessment (symptom and endoscopic assessment, measurement of biomarkers of inflammatory activity and cross-sectional imaging) into robust monitoring. Furthermore, the importance of measuring and recording parameters in a standardised fashion to enable longitudinal evaluation of disease activity is highlighted.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Annual excHangE on the ADvances in Inflammatory Bowel Disease; Biomarkers; C-reactive protein; CD; CDAI; CDEIS; CRP; CT; Crohn's Disease Activity Index; Crohn's Disease Endoscopic Index of Severity; Crohn's disease; Diagnosis; Disease activity index; Endoscopy; GI; HBI; Harvey–Bradshaw Index; IBD; IBD Ahead; IBDQ; ISC; Imaging; Inflammatory Bowel Disease Questionnaire; International Steering Committee; MRI; Monitoring; QOL; SBCE; SBFT; SES-CD; Simple Endoscopic Score for Crohn's Disease; TNF; computed tomography; gastrointestinal; inflammatory bowel disease; magnetic resonance imaging; quality of life; small-bowel capsule endoscopy; small-bowel follow-through; tumour necrosis factor

Mesh:

Substances:

Year:  2013        PMID: 23562672     DOI: 10.1016/j.crohns.2013.02.005

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  37 in total

1.  A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn's disease.

Authors:  G Pellino; F Selvaggi; G Ghezzi; D Corona; G Riegler; G G Delaini
Journal:  Tech Coloproctol       Date:  2015-09-24       Impact factor: 3.781

Review 2.  The role and utility of faecal markers in inflammatory bowel disease.

Authors:  Frank S Lehmann; Emanuel Burri; Christoph Beglinger
Journal:  Therap Adv Gastroenterol       Date:  2015-01       Impact factor: 4.409

Review 3.  Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide.

Authors:  Anke Heida; K T Park; Patrick F van Rheenen
Journal:  Inflamm Bowel Dis       Date:  2017-06       Impact factor: 5.325

4.  The new simplified MARIA score applies beyond clinical trials: A suitable clinical practice tool for Crohn's disease that parallels a simple endoscopic index and fecal calprotectin.

Authors:  Joana Roseira; Ana Rita Ventosa; Helena Tavares de Sousa; Jorge Brito
Journal:  United European Gastroenterol J       Date:  2020-07-14       Impact factor: 4.623

5.  Ratio of Circulating Estrogen Receptors Beta and Alpha (ERβ/ERα) Indicates Endoscopic Activity in Patients with Crohn's Disease.

Authors:  Pablo M Linares; Alicia Algaba; Ana Urzainqui; Mercedes Guijarro-Rojas; Rafael González-Tajuelo; Jesús Garrido; María Chaparro; Javier P Gisbert; Fernando Bermejo; Iván Guerra; Víctor Castellano; María-Encarnación Fernández-Contreras
Journal:  Dig Dis Sci       Date:  2017-08-19       Impact factor: 3.199

Review 6.  Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.

Authors:  Shapur Ikhtaire; Mohammad Sharif Shajib; Walter Reinisch; Waliul Islam Khan
Journal:  J Gastroenterol       Date:  2016-02-20       Impact factor: 7.527

Review 7.  Diagnosis and management of functional symptoms in inflammatory bowel disease in remission.

Authors:  Carlos Teruel; Elena Garrido; Francisco Mesonero
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 8.  Current role of capsule endoscopy in Crohn's disease.

Authors:  Marisol Luján-Sanchis; Laura Sanchis-Artero; Laura Larrey-Ruiz; Laura Peño-Muñoz; Paola Núñez-Martínez; Génesis Castillo-López; Lara González-González; Carlos Boix Clemente; Cecilia Albert Antequera; Ana Durá-Ayet; Javier Sempere-Garcia-Argüelles
Journal:  World J Gastrointest Endosc       Date:  2016-09-16

9.  The relationship between neutrophil/lymphocyte and platelet/lymphocyte ratios with oxidative stress in active Crohn's disease patients.

Authors:  F C Eraldemir; M Musul; A E Duman; B Oztas; C Baydemir; S Hulagu
Journal:  Hippokratia       Date:  2016 Oct-Dec       Impact factor: 0.471

10.  A Pilot Study Evaluating Novel Urinary Biomarkers for Crohn's Disease.

Authors:  Shaun S Ho; Catherine Wall; Richard B Gearry; Jacqueline Keenan; Andrew S Day
Journal:  Inflamm Intest Dis       Date:  2020-10-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.